v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities    
Net loss $ (12,468,672) $ (10,604,886)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation and amortization 1,163,847 1,207,875
Impairment of long-lived assets 298,555 220,062
Provision for credit losses 9,974 546
Inventory write-downs 62,044
Stock-based compensation 195,208 238,045
Non-cash adjustment on R&D expenditure claims 124,924 (137,696)
Non-cash other operating activities (87,933) 119,519
Changes in operating assets and liabilities:    
Accounts receivable (253,850) (164,910)
Inventories 216,638 142,322
Grant receivable / deferred grant income (2,486,668)
Research and development tax incentive receivable (72,543) (209,076)
Other current assets (203,956) (329,404)
Accounts payable and accrued expenses (684,743) 2,577,151
Long-term employee benefit liabilities (34,990) 21,306
Operating lease liabilities (191,725) (271,499)
Net cash used in operating activities (11,927,222) (9,677,313)
Cash flows from investing activities    
Proceeds from sale of assets held for sale 40,158
Purchase of property and equipment (125,731) (231,838)
Net cash used in investing activities (85,573) (231,838)
Cash flows from financing activities    
Proceeds from issuance of common stock, net of issuance costs 10,699,794 4,589,866
Proceeds from issuance of common stock for warrants exercised, net of issuance costs 4,283,912 7,939
Net cash provided by financing activities 14,983,706 4,597,805
Effect of foreign exchange rates on cash and cash equivalents 1,492 27,157
Net increase (decrease) in cash and cash equivalents 2,972,403 (5,284,189)
Cash and cash equivalents, beginning of period 1,019,909 6,304,098
Cash and cash equivalents, end of the period 3,992,312 1,019,909
Non-cash investing and financing activities    
Equity issuance costs in accounts payable and accrued expenses 14,999
Operating lease assets obtained in exchange for operating lease liabilities 1,928,398
Issuance of common stock upon cashless exercise of Series F warrants $ 55